Xanomeline oxalate是一种有效的、选择性毒蕈碱受体激动剂 (SMRA)，可刺激体内的磷酸肌醇水解。 Xanomeline oxalate 可用于研究阿尔茨海默氏病。

Xanomeline oxalate is a potent and selective muscarinic receptor agonist (SMRA) and stimulates phosphoinositide hydrolysis in vivo. Xanomeline oxalate can be used for the research of Alzheimer’s disease.

Xanomeline stimulates phosphoinositide (PI) hydrolysis in the A9 L m1 cells. Xanomeline inhibits [3H]-pirenzepine ([3H]-PZ) and [3H]-oxotremorine-M ([3H]-OXO-M) binding to rat brain with Kis of 7 and 3 nM, respectively[1].

Xanomeline robustly stimulates in vivo PI hydrolysis and the effect is blocked by muscarinic antagonists, demonstrating mediation by muscarinic receptors. In mice the ED100 for Xanomeline-induced stimulation of [3H]-IP accumulation is 54 μmole/kg in hippocampus. And in rats the ED100 for Xanomeline-induced stimulation of [3H]-IP accumulation is 8.1 μmole/kg in hippocampus[1].

141064-23-5

C16H25N3O5S

371.45

LY246708 oxalate

DMSO:45mg/mL (121.1mM)
Powder: -20°C for 3 years
In solvent: -80°C for 2 years